Esperion Therapeutics ESPR Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's current ratio?
- Esperion Therapeutics (ESPR) reported current ratio of 1.5× in Q1 2026.
- How has Esperion Therapeutics's current ratio changed year-over-year?
- Esperion Therapeutics's current ratio increased by 30.0% year-over-year, from 1.2× to 1.5×.
- What is the long-term trend for Esperion Therapeutics's current ratio?
- Over 5 years (2020 to 2025), Esperion Therapeutics's current ratio has grown at a -16.0% compound annual growth rate (CAGR), from 3.7× to 1.5×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.